One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Nakamura, Tomoko ^a   Miyakoshi, Akio ^a   Fujita, Kazuya ^a   Yunoki, Tatsuya ^a   Mitarai, Keiichi ^a   Yanagisawa, Shuichiro ^a   Fuchizawa, Chiharu ^a   Hayashi, Atsushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873394477     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/154659     Document Type: Article

References (23)

1. Zarbin M. A., Current concepts in the pathogenesis of age-related macular degeneration. Archives of Ophthalmology 2004 122 4 598 614 2-s2.0-1842478123 10.1001/archopht.122.4.598 (Pubitemid 38456297)
2. Tzekov R., Lin T., Zhang K.-M., Jackson B., Oyejide A., Orilla W., Kulkarni A. D., Kuppermann B. D., Wheeler L., Burke J., Ocular changes after photodynamic therapy. Investigative Ophthalmology and Visual Science 2006 47 1 377 385 2-s2.0-33644844662 10.1167/iovs.05-0838 (Pubitemid 46780839)
3. Lai T. Y. Y., Chan W. M., Lam D. S. C., Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. American Journal of Ophthalmology 2004 137 5 826 833 2-s2.0-2342541068 10.1016/j.ajo.2003.11.079 (Pubitemid 38582034)
4. Kvanta A., Algvere P. V., Berglin L., Seregard S., Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science 1996 37 9 1929 1934 2-s2.0-0029831672 (Pubitemid 26324159)
5. Boyer D. S., Antoszyk A. N., Awh C. C., Bhisitkul R. B., Shapiro H., Acharya N. R., Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 114 2 246 252 2-s2.0-33846586501 10.1016/j.ophtha.2006.10.045 (Pubitemid 46172497)
6. Kaiser P. K., Blodi B. A., Shapiro H., Acharya N. R., Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007 114 10 1868 1875 2-s2.0-34748844162 10.1016/j.ophtha.2007.04.030 (Pubitemid 47483925)
7. Kaiser P. K., Brown D. M., Zhang K., Hudson H. L., Holz F. G., Shapiro H., Schneider S., Acharya N. R., Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. American Journal of Ophthalmology 2007 144 6 850 e4 2-s2.0-36249002808 10.1016/j.ajo.2007.08.012 (Pubitemid 350130239)
8. Husain D., Kim I., Gauthier D., Lane A. M., Tsilimbaris M. K., Ezra E., Connolly E. J., Michaud N., Gragoudas E. S., O'Neill C. A., Beyer J. C., Miller J. W., Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Archives of Ophthalmology 2005 123 4 509 516 2-s2.0-20144387561 10.1001/archopht.123.4.509 (Pubitemid 40489924)
9. Heier J. S., Boyer D. S., Ciulla T. A., Ferrone P. J., Jumper J. M., Gentile R. C., Kotlovker D., Chung C. Y., Kim R. Y., Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Archives of Ophthalmology 2006 124 11 1532 1542 2-s2.0-33750314559 10.1001/archopht.124.11.1532 (Pubitemid 44748725)
10. Mataix J., Palacios E., Carmen D. M., Garcia-Pous M., Navea A., Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency. Retina 2010 30 8 1190 1196 2-s2.0-77957559347 10.1097/IAE.0b013e3181d2f172
11. Kumar A., Gopalakrishnan K., Sinha S., Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a north indian population. A pilot Study. Retina 2008 28 9 1296 1301 2-s2.0-67649221288 10.1097/IAE.0b013e3181814482
12. Spielberg L., Leys A., Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefe's Archive for Clinical and Experimental Ophthalmology 2010 248 7 943 956 2-s2.0-77955665773 10.1007/s00417-009-1256-6
13. Dadgostar H., Ventura A. A. C. M., Chung J. Y., Sharma S., Kaiser P. K., Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009 116 9 1740 1747 2-s2.0-69249213449 10.1016/j.ophtha.2009.05.033
14. Sato T., Kishi S., Matsumoto H., Mukai R., Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. American Journal of Ophthalmology 2010 149 6 947 e1 2-s2.0-77952554392 10.1016/j.ajo.2009.12.038
15. Mitamura Y., Hirano K., Baba T., Yamamoto S., Correlation of visual recovery with presence of photoreceptor inner/outer segment junction in optical coherence images after epiretinal membrane surgery. British Journal of Ophthalmology 2009 93 2 171 175 2-s2.0-60849087340 10.1136/bjo.2008.146381
16. Michels S., Hansmann F., Geitzenauer W., Schmidt-Erfurth U., Influence of treatment parameters on selectivity of verteporfin therapy. Investigative Ophthalmology and Visual Science 2006 47 1 371 376 2-s2.0-33644839444 10.1167/iovs.05-0354 (Pubitemid 46780838)
17. Schmidt-Erfurth U., uschmidterfurth@ophtha.mu-luebeck.de Schlötzer-Schrehard U., Cursiefen C., Michels S., Beckendorf A., Naumann G. O. H., Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Investigative Ophthalmology and Visual Science 2003 44 10 4473 4480 10.1167/iovs.02-1115 (Pubitemid 37186285)
18. Kaiser P. K., pkkaiser@aol.com Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009 116 4 747 755 10.1016/j.ophtha.2008.12.057
19. Moutray T., Alarbi M., Mahon G., Stevenson M., Chakravarthy U., Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. British Journal of Ophthalmology 2008 92 3 361 364 2-s2.0-40549112332 10.1136/bjo.2007.123976 (Pubitemid 351363531)
20. Arias L., Pujol O., Berniell J., Rubio M., Roca G., Castillo L., Acebes E., Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. British Journal of Ophthalmology 2005 89 3 312 315 2-s2.0-14744267295 10.1136/bjo.2004.050997 (Pubitemid 40327615)
21. Kitaya N., Hikichi T., Kagokawa H., Takamiya A., Takahashi A., Yoshida A., Irregularity of photoreceptor layer after successful macular hole surgery prevents visual acuity improvement. American Journal of Ophthalmology 2004 138 2 308 310 2-s2.0-3843149371 10.1016/j.ajo.2004.03.004 (Pubitemid 39037446)
22. Baba T., Yamamoto S., Arai M., Arai E., Sugawara T., Mitamura Y., Mizunoya S., Correlation of visual recovery and presence of photoreceptor inner/outer segment junction in optical coherence images after successful macular hole repair. Retina 2008 28 3 453 458 2-s2.0-40449100090 10.1097/IAE.0b013e3181571398 (Pubitemid 351354947)
23. Iriyama A., Obata R., Inoue Y., Takahashi H., Tamaki Y., Yanagi Y., Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy. Graefe's Archive for Clinical and Experimental Ophthalmology 2008 246 3 339 344 2-s2.0-39049112514 10.1007/s00417-007-0667-5 (Pubitemid 351247982)